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Abstract
For decades, it has been acknowledged that oxidative stress due to free radical species contributes to the
pathophysiology of aging and neurodegenerative diseases. Aldehyde dehydrogenases (ALDH) not only
transform aldehydes to acids but also act as antioxidant enzymes. However, little is known about the
implications of the enzymatic family of ALDH in the context of neurodegenerative processes such as
Alzheimer's disease (AD). We therefore examined the enzymatic activity of the mitochondrial
ALDH-isoform in different regions of the postmortem brain tissue isolated from patients with AD and
controls. We found that the mitochondrial ALDH activity was significantly increased only in the
putamen of patients suffering from AD compared to controls. This is of particular interest since
mediators of oxidative stress, such as iron, are increased in the putamen of patients with AD. This study
adds to the body of evidence that suggests that oxidative stress as well as aldehyde toxicity play a role in
AD.
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ABSTRACT 
 For decades, it has been acknowledged that oxidative stress due to free radical species 
contributes to the pathophysiology of aging and neurodegenerative diseases. Aldehyde 
dehydrogenases (ALDH) not only transform aldehydes to acids but also act as antioxidant 
enzymes. However, little is known about the implications of the enzymatic family of ALDH in 
the context of neurodegenerative processes such as Alzheimer’s disease (AD). We therefore 
examined the enzymatic activity of the mitochondrial ALDH-isoform in different regions of the 
postmortem brain tissue isolated from patients with AD and controls. We found that the 
mitochondrial ALDH activity was significantly increased only in the putamen of patients 
suffering from AD compared to controls. This is of particular interest since mediators of 
oxidative stress, such as iron, are increased in the putamen of patients with AD. This study adds 
to the body of evidence that suggests that oxidative stress as well as aldehyde toxicity play a role 
in AD.  
 
Keywords: aging, aldehydehydrogenase, Alzheimer’s disease, dementia, free radicals, 
mitochondria, oxidative stress  
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INTRODUCTION 
 In Alzheimer’s disease (AD), increased toxic damage to the brain due to increased reactive 
aldehydes (RA) has been associated with neuropathological hallmarks of the disease such as 
neurofibrillary tangles and neuritic plaques [1]. RA are highly reactive transient molecules, 
which are induced by endogenous and exogenous processes (Figure 1a-c). If not properly 
degraded, RA target cell membranes and induce lipid peroxidation, modify enzyme function, 
inducing mitochondrial dysfunction, and induce oxidative stress, which is also mediated by 
increased cerebral iron, leading to apoptosis [2]. Both oxidative stress and aldehyde toxicity have 
been acknowledged to play a key role in the pathophysiology of neuropsychiatric disorders and 
AD via lipid peroxidation and DNA strand brakes [3-12]. Oxidative stress refers to an imbalance 
within cells, where more reactive oxygen species (ROS) are produced than are detoxified, 
leading to cell damage and death [13,14]. 
 One of the most important pathways for aldehyde detoxification is their oxidation by 
aldehyde dehydrogenase (ALDH, [EC 1.2.1.3.]). ALDH is a well known enzyme with pyridine-
nucleotide-dependent oxidoreductase activity which is important for the metabolism of aldehyde 
substrates in numerous species [15].  
 The ALDH superfamily includes NAD(P)+-dependent enzymes catalyzing the oxidation of a 
wide spectrum of aliphatic and aromatic aldehyde substrates generated from various endogenous 
and exogenous precursors to their corresponding carboxylic acids. Endogenous aldehydes are 
formed during the metabolism of vitamins, steroids, lipids, amino acids, neurotroansmitters, 
biogenic amines and in the process of lipid peroxidation (Figures 1b,c). Exogenous aldehydes are 
formed during the metabolism of numerous agents such as alcohol, drugs and environmental 
agents (Figure 1a).  
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 In AD, one special focus has been on one of the isoenzymes, the mitochondrial ALDH 
(ALDH2). This isoenzyme of ALDH is located in the mitochondrial matrix and is considered to 
be principally responsible for the oxidation of acetaldehyde which is produced during different 
endogenous and exogenous processes mentioned above. It is involved in the metabolism of 
biogenic aldehydes produced by monoamines and oxidase-catalyzed deamination of 
catecholamines and indoleamines [15-17]. Furthermore, dicarbonyl compounds such as 
methylglyoxal or glyoxal are also substrates for ALDH. These compounds have been implicated 
in the pathogenesis of AD [18,19].  
  A functional polymorphism of the mitochondrial aldehyde dehydrogenase gene (ALDH2 1/2 
polymorphism) can influence the accumulation of acetaldehyde which may play a role in 
Alzheimer’s disease (AD) and has a high prevalence among Mongoloids [20-22]. The results of 
the association studies were varying among different Asian subpopulations. An association with 
late-onset AD (LOAD), interacting synergistically with the presence of the apolipoprotein E 
allele 4 (APOE ε4) has been detected in Japanese and Chinese subjects, whilst it was not 
reported in a population of Koreans [20-24]. A longitudinal study found that the incidence of AD 
in healthy participants was not correlated with ALDH polymorphism within 2.4 years [24]. In the 
mouse model, it has been shown that a deficiency in mitochondrial ALDH2 leads to age 
dependent memory impairment and increased lipid peroxidation [25]. Furthermore, these animals 
show the same neuropathology, namely hyperphosphorylation as well as plaques and tangles, as 
seen in humans with AD [25].  
 It has been suggested that mitochondrial ALDH influences the pathophysiology of AD in 
several ways. First of all, it influences aldehyde toxicity directly, secondly it significantly 
contributes the overall antioxidative potential on a cellular level, and thirdly it interferes with 
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various neurotransmitters that are decreased in the context of AD. All these different 
mechanisms are well known to play a pivotal role in AD. However, to this date, mitochondrial 
ALDH is not one of the well-studied antioxidant players that scientists expected to find fighting 
free-radical damage. Little is known about the activity and function of this enzyme in the brain 
of patients with AD [26]. For this reason, it is worth examining the activity of mitochondrial 
ALDH more closely in this context. We have therefore studied the enzyme activity of 
mitochondrial ALDH in the cerebral cortex as well as the putamen of patients with AD since 
both regions are known to play a role in AD and have an increased iron concentration, which 
mediates oxidative stress in both aging and AD [27-29].  
 
MATERIALS AND METHODS 
Brain tissue samples 
 The activity of the mitochondrial aldehydedehydrogenase, ALDH, in the human brain was 
measured in postmortem brain tissue of 14 elderly patients with mostly final stages of AD (9 
females, 5 males, mean age: 81.6±4.4 years) and 12 age-matched controls (8 females, 4 males, 
mean age: 80.8±4.4 years) without any medical history of psychiatric or neurological diseases. 
Two of the age-matched controls showed neurofibrillary tangles and senile plaques. The patients 
fulfilled the diagnostic criteria of the International classifications of disease for AD [30]. 
Additionally, the diagnosis was verified via postmortem examination for senile plaques and 
neurofibrillary tangles [31]. None of the brains examined had signs of other neurodegenerative 
diseases such as Parkinson’s disease (PD). The brain regions investigated were the frontal cortex 
and the putamen. Brain samples from Caucasian German speaking patients were matched with 
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control samples according to age, gender, and postmortem delay (See Tables 1, 2, and 3 for 
details). 
 The postmortem brain tissue was collected via autopsies performed at the Department of 
Psychiatry, Hospital, Mauer, Austria and at the Institute of Forensic Medicine, University of 
Würzburg, Germany. All procedures were in accordance with the NIH Guide for the Care and 
Use of Laboratory human tissue and were approved by the Ethics committee of the University of 
Würzburg, Germany and were also in accordance with the declaration of Helsinki.  
 
Tissue extraction 
 The brain tissue was obtained according to a standardized procedure [32]. The left 
hemisphere was freshly frozen at -80°C. For further neuropathological investigations, the right 
hemisphere was kept in formalin. Freshly frozen brain extracts were prepared by homogenization 
in 10 volumes (w/v) of 0.25 M saccharine with a Polytron homogenizer at 1000 rpm followed by 
sonification (Branson). After this procedure, centrifugation (600g for 10 min) was carried out for 
10 min at 4°C. The cellular debris was then re-suspended with 0.25M sucrose and the 
supernatant was centrifuged for another 10 min (15000g at 4°C; Sorvall RC-5C). The cellular 
debris was then re-suspended again with 0.25M saccharine and then sonified. The supernatants 
were centrifuged for another 60 min (100,000g, 4°C Beckmann L3-50). The sediment with the 
mitochondrial fraction was re-suspended with 0.25M. 
 
 7 
 
Protein quantification  
 For protein quantification of the brain homogenate, the protein assay kit provided by BioRad 
on the basis of the method previously described [33] was used. Colorimetric visualization was 
carried out at 595 nm. 
 
Mitochondrial ALDH Activity 
 The mitochondrial ALDH activity (nmol/min/mg protein) was determined using a 
colorimetric method modified according to the protocol described before [34]. Briefly, 50 mM 
sodiumpyrophosphate-buffer (pH 8.8), 0.5 mM NAD+, 1 mM EDTA, 10 mM 2-
Mercaptoethanol, 2 µM Rotenon (1% of total volume), 0.5 % Triton X-100 and freshly prepared 
homogenate were used as reactant and the substrate indol-3-acetaldehyde (IAA) was added to 
start the reaction. 1 mg of the brain homogenate and 0.4 mg of the mitochondrial fraction were 
added to the reagent-substrate mixture. We later omitted the mitochondrial fraction to calculate 
the result for the cytosolic fraction (data not shown). The change in optical density at 340 nm 
(37°C) was measured over time (20 min) by a spectrophotometer (552S UV/VIS; Perkin-Elmer, 
USA) to obtain the ALDH activity (Lambert-Beer law). The activity was calculated by the PC 
connected to the photometer using both the standard curve and the extinction coefficient 
(Lambert-Beer law).  
 
Statistics 
 We compared the different ALDH activities between the index-group (patients with AD) and 
age matched control-group using student’s t-test on the statistical software graph-pad-prism 
version 4. 
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 The influence of independent variables such as gender, age, and postmortem delay was tested 
using covariance analysis (ANCOVA). In addition, we examined the relation of age and ALDH 
activity by performing Pearson Product Moment Correlation. Significance was set at p-value < 
0.05. 
 
RESULTS 
 The mitochondrial ALDH activity (mean±SEM in mmol/min/mg protein) was significantly 
(p<0.029, df=22) elevated in the putamen of the AD group (7.60±0.54, 22) compared to the 
control group (5.9±0.45) (See Figure 2). In the frontal cortex, we were not able to detect any 
significant differences between the groups (AD: 8.29±0.49; controls: 8.07±0.43, p >0.74, df=24). 
The effect size for the putamen was 0.2 and for the frontal cortex 0.13. 
 Although patients and controls were carefully pair-matched, we examined the influences of 
confounding parameters such as age, gender, medication, and postmortem delay on ALDH 
activities. There was no significant correlation with postmortem time (0.41<rho<0.36; 
0.19<p<0.96) nor age (-0.49<rho<0.52; 0.11<p<0.94) in any of the investigated brain regions. 
 
DISCUSSION 
 In our study, we found that mitochondrial ALDH-activity was significantly higher in the 
putamen of patients with AD. Our results are in line with previous studies suggesting a role of 
ALDH in the pathogenesis of AD [20-23,26]. 
 Our results of an alteration of the mitochondrial ALDH activity in the brain of patients with 
AD are supported by earlier findings of Picklo and colleagues [26] who also found the ALDH 
activity to be significantly elevated in the brain of patients with AD. This group reported a 
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significant increase of ALDH in the temporal cortex of patients with AD in a significantly 
smaller sample of only four patients with AD [26]. To the best of our knowledge, we are the first 
to describe an increase of mitochondrial ALDH in the putamen of a patient with AD. This study 
suggested that increased mitochondrial ALDH expression might be due to increased highly 
reactive intermediates or pro-oxidants in AD, since mitochondria are one of the main sources of 
free radicals in organs [26]. Earlier studies on ALDH in AD have suggested that increased 
ALDH activity, as we found in the putamen, might play a main role in the formation of senile 
plaques [26].  
 A number of reasons could be responsible for the increased mitochondrial ALDH activity 
that we report in the putamen of patients with AD. First, it might be a result of increased 
production of aldehydes due to an increase of monoamine oxidase B (MAO-B), which has been 
reported in the context of AD [35]. Furthermore, the increased ALDH activity, together with an 
elevated MAO-B activity, could be responsible for a higher dopamine turnover and an increased 
oxidative stress which has been found in the putamen of patients with AD [35-37]. The latter 
induces MAO-B activity, via a positive feed-back loop and in turn increases oxidative stress and 
neurodegeneration [37,38].  
 Second, in the context of AD, serotonergic, dopaminergic, and noradrenergic neurons 
degenerat, due to multiple factors, e.g., disruption in neurotrophic factors, and increased iron 
mediated oxidative stress [37,39,40]. These neurodegenerative processes warrant an increase of 
the metabolizing enzymes, e.g., aldehyde dehydrogenases AD [41]. 
 Thirdly, it has been reported that the putamen in particular contains large quantities of iron 
which increase with age [29]. Furthermore, in AD, iron deposits in the putamen have been 
reported to be significantly elevated in subjects with cognitive deficits [27,28]. Since iron plays a 
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pivotal role in oxidative stress, increased iron content in the putamen of patients with AD could 
contribute to elevated oxidative stress, which in turn could increase both ROS and RAs. Both 
could then lead to neurodegeneration which is described in the context of AD [30,39,42]. The 
increase of RA might warrant metabolism catalyzed by increased mitochondrial ALDH [41]. 
However, we did not measure the iron content of the putamen in our study. 
 Finally, several studies suggest that alcohol intake affects the development of AD [43], 
because ethanol and its metabolite, acetaldehyde, are directly neurotoxic. Therefore, a 
dysregulation of ALDH leading to a disruption of the ethanol mechanism resulting in increased 
aldehyde toxicity might contribute the development of AD in the context of increased alcohol 
intake (ADH) [43]. However, since none of our AD subjects had a significant history of alcohol 
addiction, external ethanol intake might play only a minor role in the increase of mitochondrial 
ALDH that we found in the putamen of the index group.  
 Similar to what we observed with ALDH, increased expression of enzymes to detoxify ROS 
have been reported earlier in AD. One example is manganese superoxide dismutase (Mn-SOD) 
which is localized in the mitochondria and catalyzes the detoxification of superoxide [36].  
We did not find a significant correlation with either the postmortem time or age and ALDH 
activity. This is suggestive of a high postmortem stability of the enzyme as has been reported 
before [44].  
 Our study is the first to report a significantly increased mitochondrial ALDH activity in the 
putamen of patients with AD. However, the role of neuroprotection and degeneration in AD 
remains complex since neuroprotective agents such as ALDH, neurotrophic factors, and their 
interaction with oxidative stress in AD play an important role and have to be examined in further 
studies [39,40,45].  
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 The significance of our current examinations is highlighted by a recent study showing that 
treatment with methylene blue (methylthioninium chloride) may postpone or reverse 
neurodegeneration in AD [46]. Methylene blue inhibits tau aggregation and works as a hydrogen 
ion scavenger, an inhibitor of nitric oxide synthase as well as an inhibitor of the enzyme MAO 
[47]. Both pathomechanisms are linked to oxidative stress as well as aldehyde toxicity and the 
function of ALDH. Therefore, the therapeutic effect of methylene blue may be linked to its 
ability to reduce oxidative stress and or aldehyde toxicity. 
 It is pivotal to carry out further studies linking possible mutations of the ALDH genes and 
treatment outcome in AD. This has been carried out previously for other diseases that are linked 
to ALDH and lead to neuronal damage or loss such as alcohol dependence [48]. Thus, the 
metabolism of aldehyde, including the key enzyme mitochondrial ALDH, could be a new target 
for preventive and therapeutic strategies in AD. However, so far, there are only few studies on 
the subject and further investigations are needed for a better understanding of the complicated 
interactions of this family of enzymes, namely ALDH, to explore future therapeutic implications.  
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Table 1. Sample characteristics and activity of ALDH in the frontal cortex and the putamen. 
 
  Number Age Gender
F/M 
Postmortem Cortex 
frontalis 
p Putamen p 
Control 12 80.8±7.5 8/4 8.2±5.1 8.07±0.43 5.9±0.45 
AD 14 81.6 ± 4.4 9/5 9.4±9.5 8.29±0.49
>0.7 
7.60±0.54
<0.03 
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Table 2. Demographic and neuropathological data of patients with AD 
 
Diagnosis Age Sex PM Cause of death Neuropathology/ 
Stage of disease 
AD 81 F 18 Pneumonia 
Cardiac arrest 
Cerebral atrophy, 
Final stage of AD 
AD 82 M 12 Pneumonia 
Cardiac arrest 
Final stage AD 
 
AD 83 M 6 Pulmonary embolism Cerebral Atrophy, internal 
hydrocephalus Final stage AD 
AD 80 F 15 Sepsis Cerebral Atrophy 
Final stage AD 
AD 80 F 4.5 Pulmonary embolism Cerebral Atrophy 
Final stage AD 
AD 72 F 3 Sepsis 
 
Cerebral Atrophy, micro-
vascular cerebral infarction, 
AD 
AD 86 F 38 Pulmonary embolism Diffuse cerebral Atrophy 
AD (NS) 
AD 86 M 9 Pneumonia Diffuse cerebral Atrophy 
AD (NS) 
AD 77 M 3.5 Cardiac arrest Atrophy 
Cerebral arteriosclerosis 
AD 
AD 88 F 3 Pulmonary embolism Diffuse cerebral Atrophy 
Final stage AD 
AD 84 F 5 Cardiac arrest Diffuse cerebral Atrophy 
Final stage AD 
 
AD 76 M 6 Pneumonia, Cardiac 
arrest 
Cerebral Atrophy 
Final stage AD 
AD 84 F 5 Pneumonia, Cardiac 
arrest 
Cerebral Atrophy 
Final stage AD 
AD 83 F 3 Ileus Cerebral Atrophy 
Final stage AD 
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Table 3. Demographic and neuropathological data of controls. 
 
Group Age Sex PM Cause of death Neuropathology 
C 80 F 3.00 Pulmonary embolism - 
C 87 F 15.00 Cardiopmopathy Regular aged brain with a few 
fibrillary tangles 
C 78 F 12.00 Pulmonary embolism 
Cardiac arrest 
- 
C 88 M 10.50 Pneumonia, 
Pulmonary embolism 
- 
C 72 F 3.00 Pulmonary embolism - 
C 85 F 13.00 Cardiac arrest - 
C 80 M 5.10 Acute cardial 
dilatation, stroke 
Regular aged brain with a few 
fibrillary tangles 
C 90 M 17.00 Cardiac arrest, 
Pneumonia 
- 
C 86 F 5.50 Pulmonary embolism - 
C 63 F 6.50 Bronchial carcinoma, 
metastasis 
- 
C 80 F 4.00 NK - 
C 80 M 3.50 Cardiac arrest 
Sepsis 
- 
 
 
 
 
 
 
 
 22 
 
FIGURE LEGEND 
 
Figure 1. (a,b,c) The metabolism of ALDH, an exogenous ethanol-metabolism; (b) 
neurotransmitter metabolism; (c) ALDH is detoxifying toxic aldehydes in the lipid peroxidation 
process. 
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